Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer.

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 13, 2025

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer.

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 13, 2025

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Journal: EClinicalMedicine
Published: July 15, 2025

Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS).

Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS).

Journal: Scientific reports
Published: July 09, 2025

PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine Resistance.

PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine Resistance.

Journal: bioRxiv : the preprint server for biology
Published: June 04, 2025

Identification of novel selective estrogen receptor degraders (SERD) via physics-based and deep-learning-based virtual screening and Bioassys.

Identification of novel selective estrogen receptor degraders (SERD) via physics-based and deep-learning-based virtual screening and Bioassys.

Journal: Bioorganic chemistry
Published: April 25, 2025

Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer.

Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer.

Journal: Genes & development
Published: April 21, 2025

ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.

ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.

Journal: Cancer research
Published: April 13, 2025

Novel Polymorphic Patterns for Elacestrant Dihydrochloride.

Novel Polymorphic Patterns for Elacestrant Dihydrochloride.

Journal: Pharmaceutics
Published: March 25, 2025

Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries.

Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries.

Journal: NPJ breast cancer
Published: March 12, 2025

Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.

Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.

Journal: Cancers
Published: March 05, 2025

Clinical Actionability of Molecular Targets in Multi-Ethnic Breast Cancer Patients: A Retrospective Single-Institutional Study.

Clinical Actionability of Molecular Targets in Multi-Ethnic Breast Cancer Patients: A Retrospective Single-Institutional Study.

Journal: Molecular diagnosis & therapy
Published: March 03, 2025
Showing 1-12 of 97

Last Updated: 01/07/2026